PARTICIPA

PARTICIPA

martes, 15 de noviembre de 2016

manuel sanchez molla compartió un enlace: Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or without pulmonary function testing

manuel sanchez molla compartió un enlace: Evolocumab and Coronary Disease Progression in Statin-Treated Patients | Cardiology | JAMA | The JAMA Network



Enviado desde mi iPad

CAMBIOS CRIBADO CANCER CERVIX

http://appswl.elsevier.es/publicaciones/item/pdf/watermark?idApp=UINPBA00004N&piiItem=S021265671630419X&origen=zonadelectura&web=zonadelectura&urlApp=http://www.elsevier.es&estadoItem=S300&idiomaItem=es&textMensaje=Documento%20descargado%20de%20http://www.elsevier.es%20el%2015-11-2016

lunes, 7 de noviembre de 2016

analisis de las GUIAS OSTEOPOROSIS

Al parecer las guias se centran mas en variables subrogadas como densitometria que en riesgo de fractura que parece lo razonable.


Management recommendations for osteoporosis in clinical guidelines

Authors

Summary


Objective

Numerous guidelines advise about management of osteoporosis, but little research has been conducted on their recommendations. We analysed recommendations on management of bone health in clinical guidelines.

Design

We surveyed recommendations on assessment, treatment and monitoring of bone health in 78 clinical guidelines (22 primary focus osteoporosis, 56 primary focus not osteoporosis) lodged at the Agency for Health Research and Quality National Guidelines Clearinghouse between 1/1/2009 and 12/31/2014.

Measurements

Governance of guidelines; discussion of fracture risk in the target population; recommendations for assessment, treatment and monitoring of bone health.

Results

Only 14% of guidelines discussed fracture risk in the target population. When guidelines discussed assessment, 98% recommended bone mineral density (BMD) measurement but only 27% recommended estimation of fracture risk. When guidelines discussed treatment, 63–71% recommended calcium and/or vitamin D, while <12% recommended avoiding low body weight or smoking cessation. When guidelines discussed intervention, 53% did so on the basis of BMD measurement, and only 27% on the basis of estimated fracture risk. When guidelines discussed monitoring, >90% recommended BMD measurements, and only 3% recommended estimation of fracture risk. About 65% of guidelines that suggested a BMD monitoring interval recommended one of ≤3 years. Compared to guidelines with a primary focus on osteoporosis, guidelines whose primary focus was not osteoporosis were less likely to discuss fracture risk in the target population (2% vs 45%), recommend estimation of fracture risk (11% vs 55%) and recommend intervention on the basis of estimated fracture risk (10% vs 67%) (all P < 0·005).

Conclusions

Our findings highlight a strong focus in clinical guidelines on BMD, a surrogate measure, rather than fracture risk, the clinically important outcome, particularly when bone health is not the primary focus. Addressing this issue might facilitate more rational use of resources and improve patient care.